Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer

Hayes, Daniel F.; Walker, Teresa M.; Singh, Baljit; Vitetta, Ellen S.; Uhr, Jonathan W.; Groß, Steven; Rao, Chandra; Doyle, Gerald V.; Terstappen, Leonardus Wendelinus Mathias Marie

doi:10.3892/ijo.21.5.1111

Cited by 93 publications

(93 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, genetic changes can be detected in CTCs, including abnormal telomerase activity (Soria et al, 1999), allelic loss and/or amplification of multiple oncogenes not seen in normal control populations (Austrup et al, 2000), and aneuploid changes in cellular chromosome content based upon FISH analysis similar to those seen in the primary tumour (Fehm et al, 2002). Additionally, cancer-associated protein expression by CTCs can be detected, such as HER2 (Figure 2) (Hayes et al, 2002). Interestingly this report also suggests an inverse relationship between the level of HER2 expression and the expression of cytokeratin.…”

Section: Future Directionsmentioning

confidence: 58%

See 1 more Smart Citation

The measurement and therapeutic implications of circulating tumour cells in breast cancer

2005

View full text Add to dashboard Cite

Circulating tumours cells (CTCs) represent an important biologic link in the spread of breast cancer from primary to metastatic disease. CTCs are strong predictors of prognosis in patients with metastatic breast cancer. Research to date has focused on development of methods with adequate sensitivity and specificity to reproducibly identify these rare events. Future research will focus on the biologic phenotypes of these cells with goals to understand mechanisms of metastasis, to identify novel therapeutic targets, and to monitor response to therapy.

show abstract

Section: Future Directionsmentioning

confidence: 58%

“…Only the CECs are shown in the panels. Reproduced with permission from (Hayes et al, 2002). (Cristofanilli et al, 2004).…”

Section: Current Clinical Status Of Ctcsmentioning

confidence: 99%

The measurement and therapeutic implications of circulating tumour cells in breast cancer

2005

View full text Add to dashboard Cite

show abstract

“…It is clear that patients with early detection of cancer have better rate of recovery and survival than patients with more advanced cancer [35]. It has already been shown that approximately 15-20 % of breast cancers have amplification of the HER2/neu gene or over expression of its protein product.…”

Section: Discussionmentioning

confidence: 99%

“…It has already been shown that approximately 15-20 % of breast cancers have amplification of the HER2/neu gene or over expression of its protein product. An inverse relationship between the level of HER2 expression and the expression of cytokeratin has been shown [35]. In addition, evaluation of changes in markers during the process of the disease and prognostic value of the markers needs more survey.…”

Section: Discussionmentioning

confidence: 99%

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Oloomi

Bouzari

Mohagheghi

et al. 2012

Cancer Microenvironment

View full text Add to dashboard Cite

A biomarker is a quantifiable laboratory measure of a disease specific biologically relevant molecule that can act as an indicator of a current or future disease state. The purpose of this study is to detect the expression of RNA biomarkers using Cytokeratin 19 (CK-19), Mammaglobin (MAM), Carcinoembryonic antigen (CEA), Mucin (MUC), C-Myc, erb-B2, a proliferation marker (Ki-67), Epidermal growth factor receptor (Her2/neu) and Estrogen receptor (ER) in Iranian women who were diagnosed with breast cancer. In this study, 90 samples; 60 cancer patients and 30 healthy controls were considered. 73.4 % patients were in stage I/II and 26.6 % were in stage III/IV. Patients were selected prior to the administration of any adjuvant systemic therapy. Total RNA extraction was obtained from peripheral blood of each patient and healthy control. Reverse transcription polymerase chain reaction (RT-PCR) method was used for detection of mRNA of the selected biomarkers of circulating breast cancer cells in blood. Molecular characterization is assessed as a method for early detection of breast cancer. For this purpose, eleven specific primers were selected and RT-PCR was used. The data of RT-PCR revealed that expression of MUC1, CK19, CEA, MAM, erbB-2, Ki67 and C-Myc biomarkers were significantly different between breast cancer patients and healthy controls. On the other hand, ERα, ERβ and Her2 markers were not significantly different between the two mentioned groups.

show abstract

“…First attempts to characterize CTC have been successful and are becoming more important in the development of targeted therapies [19][20][21][22][23][24][25] . Figure 4 shows examples of the presence of a target protein and or its gene amplifi cation on CTC.…”

Section: Clinical and Translational Leadsmentioning

confidence: 99%

Monitoring and Characterization of CTC in Cancer Patients

Miller¹,

Doyle²,

Terstappen³

2008

AACR Education book

View full text Add to dashboard Cite

Concomitant with the rapidly growing number of treatment options for patients with metastatic carcinomas is the need for biomarkers to guide and monitor their use. Tumor cells shed into the blood during metastasis may help meet this need by serving as generic biomarkers for a variety of carcinomas. Indeed, assessment of circulating tumor cells (CTC) has already been shown to provide prognostic information regarding progression free and overall survival in metastatic breast (MBC), colorectal (MCRC), and prostate cancer (MPC). Th is has been made possible by the introduction of the CellTracks® system, which has provided a standardized method for the enumeration and characterization of CTC. In addition to predicting outcomes and monitoring treatment, CTC have also been used to detect the presence of treatment targets. Th e use of CTC as a source of tumor tissue can provide real-time information helpful in selecting specifi c therapies or families of therapies making CTC an invaluable tool in the practice of evidence-based personalized medicine. Background and Materials

show abstract

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer

Cited by 93 publications

References 33 publications

The measurement and therapeutic implications of circulating tumour cells in breast cancer

The measurement and therapeutic implications of circulating tumour cells in breast cancer

Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer

Monitoring and Characterization of CTC in Cancer Patients

Contact Info

Product

Resources

About